Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 Europe Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 Europe Idiopathic Pulmonary Fibrosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
Chapter 4. Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 Europe Pirfenidone Market by Country
4.2 Europe Nintedanib Market by Country
Chapter 5. Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 Europe Retail Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
5.3 Europe Online Providers Market by Country
Chapter 6. Europe Idiopathic Pulmonary Fibrosis Market by Country
6.1 Germany Idiopathic Pulmonary Fibrosis Market
6.1.1 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.2 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 UK Idiopathic Pulmonary Fibrosis Market
6.2.1 UK Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.2 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 France Idiopathic Pulmonary Fibrosis Market
6.3.1 France Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.2 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 Russia Idiopathic Pulmonary Fibrosis Market
6.4.1 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.2 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.5 Spain Idiopathic Pulmonary Fibrosis Market
6.5.1 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type
6.5.2 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.6 Italy Idiopathic Pulmonary Fibrosis Market
6.6.1 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type
6.6.2 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.7 Rest of Europe Idiopathic Pulmonary Fibrosis Market
6.7.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
6.7.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
Unique Offerings 